-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Benzinga·10/19/2026 17:12:38
Listen to the news
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.